Treatment of Plantar Warts

NCT ID: NCT05198180

Last Updated: 2022-01-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-28

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to compare the efficacy and safety of topical 30% potassium hydroxide solution and topical 45% hydrogen peroxide solution in treatment of plantar warts.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plantar Wart

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Potassium hydroxide group

Patients with plantar warts will apply topical 30% potassium hydroxide solutions on warts

Group Type ACTIVE_COMPARATOR

Topical 30%Potassium hydroxide solution

Intervention Type DRUG

Patients will apply the solution every day under occlusion for 3 months

Hydrogen peroxide group

Patients with plantar warts will use topical 45% hydrogen peroxide solution on warts

Group Type ACTIVE_COMPARATOR

Topical 45% hydrogen peroxide solution

Intervention Type DRUG

Patients will apply the solution every day under occlusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Topical 30%Potassium hydroxide solution

Patients will apply the solution every day under occlusion for 3 months

Intervention Type DRUG

Topical 45% hydrogen peroxide solution

Patients will apply the solution every day under occlusion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* confirmed diagnosis by clinical and dermoscopic examination of plantar warts

Exclusion Criteria

* history of hypersensitivity to any component used in this study
* pregnancy and breastfeeding
* patients who receive immune suppressive therapy
* patients who received any wart treatments during the last 2 months before enrollent in the study
* patients who refused participation in the study
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sohag University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Samar Sayed Ahmed

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sohag faculty of medicine

Sohag, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Samar Sa Ahmed, Resident

Role: CONTACT

01152471005

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Samar Sa Ahmed, Resident

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Sohag-Mes-21-11-07

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.